Company: TBMC
Filing Date: 2025-03-25
Form Type: 10-K
Source: 0001013762-25-002139
Chunk: 237

Company: Trailblazer Merger Corp I
Filing Date: 2025-03-25
Form: 10-K
Item: Item 1B
Chunk 237
---
 were previously employed by LH Financial. LH Financial is winding down
its operations. Mr. Rabinowitz served as Vice President and Chief Investment Officer of LH Financial from inception in 1997 until 2010.
From 2010 until February 2025 Mr. Rabinowitz served as Chief Executive Officer of LH Financial. LHX evaluates investment opportunities
in a wide variety of asset classes including public companies, private companies, development stage companies, technology institutions,
startup incubators, and other ventures to determine if they fit within the framework of the family office’s investment criteria.
LHX., under the guidance of Mr. Rabinowitz, subsequently facilitates investments and exits from investments approved by the family. LHX
also participates and facilitates charitable endeavors for itself and the family in many charitable causes, including organizations that
foster education, family, and health across North America, Israel, and elsewhere. Mr. Rabinowitz advises, on a pro bono basis, a charity
organization in the U.S. and Israel. In addition, Mr. Rabinowitz serves on the board of directors for Areivim, Inc., a community committed
to the well-being of at-risk children, their parents, and siblings. Mr. Rabinowitz is the founder and CEO of ACR Foundation, a 501(c)3
registered charitable trust focused on both local and international charitable causes. Mr. Rabinowitz is the father-in-law of Mr. Eichorn.
Mr. Rabinowitz graduated from Lander College of Arts & Sciences with a BS in Mathematics.

Scott Burell - Chief Financial Officer

Since August 2018, Scott Burell
has been the Chief Financial Officer of AIVITA Biomedical, Inc., an Irvine California-based immuno-oncology company focused on the advancement
of commercial and clinical-stage programs utilizing curative and regenerative medicines. From November 2006 until its sale to Invitae
Corp. (NYSE: NVTA) in November 2017, Mr. Burell was the Chief Financial Officer, Secretary and Treasurer of CombiMatrix Corporation (NASDAQ:
CBMX), a family health-focused clinical molecular diagnostic laboratory specializing in pre-implantation genetic screening, prenatal diagnosis,
miscarriage analysis, and pediatric developmental disorders. Mr. Burell successfully led the split-off of CombiMatrix in 2007 from its
former parent, has led several successful public and private debt and equity financing transactions as well as CombiMatrix’s reorganization
in